Orthofix Medical, Inc.
$11.6M 12,682 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Genmab A/S
Genmab A/S reported $11,649,525.69 across General Payments, Research, and Ownership to 1 physicians and teaching hospitals across 2,593 transactions.
- $11.6M Top 10% payer
- All-tracks total
- 2,593 Top quartile volume
- Transactions
- 1 Below-median reach
- Recipients
- #149
- of 1,925 companies
Genmab A/S reported $11,649,525.69 across all CMS Open Payments tracks (General + Research + Ownership) to 1 physicians and teaching hospitals in Program Year 2024 - ranking #149 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $350.00, averaging $11.6M per recipient.
How Genmab A/S's $11.6M all-tracks total breaks down
Genmab A/S's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
37/100
Total payments
A
100/100
Transaction volume
F
29/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer genmab-a-s Genmab A/S
$11.6M · #149/1,925 · 0.1% industry · PY2024
- TOT $11.6M
- RANK #149
- SHARE 0.1%
- TXN 2,593
- RCP 1
- CAT 1
- GEN $350.00
- TOP1 100.0%
- PY 2024
Volume peers
Nearest volume peer: Orthofix Medical, Inc. ($11.6M)
Genmab A/S sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Genmab A/S
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Genmab A/S, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 1-category general-payment breakdown below at $350.00 (100.0% of General Payments, 1 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 1 types of general payments, Genmab A/S's largest category was "Consulting Fee" at $350.00 - 100.0% of General Payments.
How Genmab A/S divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $350.00 | 1 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $350.00 (100.0%) of $350.00 in this company's General Payments records across 1 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Genmab A/S
The five named recipients with the highest reported General Payments from this company
- 1
Gilles Salles
$350.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Genmab A/S's spend rank (#149 of 1,925, top 8% by spend) and concentration rank (#130 of 1,838, top 7% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- 3Shape A/S : $2.0K total payments, HHI 10000
- Omnia S.r.l : $752.44 total payments, HHI 10000
- Northern X-Ray Company : $3.3K total payments, HHI 10000
- Surgebright Inc. : $2.5K total payments, HHI 10000
- Swing Therapeutics, Inc. : $107.4K total payments, HHI 10000
- AERAS, Inc. : $1.5K total payments, HHI 10000
- Genmab A/S (this company) : $350.00 total payments, HHI 10000
- Ziemek Dental Laboratory, Inc. : $61.9K total payments, HHI 10000
- Archimmune Therapeutics Inc. : $897.86 total payments, HHI 10000
- Clarix Imaging Corporation : $3.7K total payments, HHI 10000
- Sentrimed, Inc. : $4.0K total payments, HHI 10000
- Nurami Medical Inc : $1.5K total payments, HHI 10000
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Genmab A/S's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Genmab A/S.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Genmab A/S.
Showing 6 of 1,924 companies with CMS-reported payment data.
Kyowa Kirin, Inc.
$11.7M 16,689 recipients
Compare payment profiles
Inari Medical, Inc.
$11.7M 48,517 recipients
Compare payment profiles
Phathom Pharmaceuticals, Inc.
$11.5M 93,370 recipients
Compare payment profiles
Catalyst OrthoScience
$11.8M 424 recipients
Compare payment profiles
Iovance Biotherapeutics, Inc.
$11.5M 604 recipients
Compare payment profiles
Put this to use
Genmab A/S ranks #149 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Genmab A/S sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Genmab A/S. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.